These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 7780049)
1. Disposition kinetics of HEPP in rats after intravenous, oral, and intraperitoneal administration. Correlation of plasma and brain levels with the anticonvulsant effect. Gómez LE; Cueva-Rolón R; Lehmann PA Biopharm Drug Dispos; 1995 Mar; 16(2):77-89. PubMed ID: 7780049 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the novel anticonvulsant HEPP after single intravenous administration of three different doses in dogs. Gómez LE; Lehmann PA Biopharm Drug Dispos; 1995 Mar; 16(2):105-12. PubMed ID: 7780044 [TBL] [Abstract][Full Text] [Related]
3. Gestational age dependency in the prenatal toxicity and in the disposition kinetics of the novel anticonvulsant HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) after subcutaneous administration in pregnant rats. Gómez-Martínez LE Int J Toxicol; 2007; 26(3):237-46. PubMed ID: 17564905 [TBL] [Abstract][Full Text] [Related]
4. Plasma determination of the novel anticonvulsant D,L-3-hydroxy-3-ethyl-3-phenylpropionamide and preliminary pharmacokinetic studies in the rat. Gomez LE; Lehmann PA J Chromatogr; 1992 Mar; 575(2):306-10. PubMed ID: 1629310 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of HEPP, a new anticonvulsant, in healthy subjects and rabbits after multiple doses. González-Esquivel DF; Pérez RM; Cook HJ Biopharm Drug Dispos; 2004 Mar; 25(2):85-90. PubMed ID: 14872556 [TBL] [Abstract][Full Text] [Related]
6. Anticonvulsant and Toxicological Evaluation of Parafluorinated/Chlorinated Derivatives of 3-Hydroxy-3-ethyl-3-phenylpropionamide. Garrido-Acosta O; Meza-Toledo SE; Anguiano-Robledo L; Soriano-Ursúa MA; Correa-Basurto J; Davood A; Chamorro-Cevallos G Biomed Res Int; 2016; 2016():3978010. PubMed ID: 27006945 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of D,L-3-hydroxy-3-ethyl-3-phenylpropionamide (HEPP) in pregnant rats at different stages of gestation and maternal-fetal disposition during late pregnancy. Fletes Mdel R; Gómez-Martínez LE Reprod Toxicol; 2003; 17(2):177-84. PubMed ID: 12642150 [TBL] [Abstract][Full Text] [Related]
8. Single dose pharmacokinetics of HEPP, a new anticonvulsant in normal healthy volunteers. González-Esquivel DF; Rubio-Donnadieu F; Carvajal-Sandoval G; Jung HC Biopharm Drug Dispos; 1998 Dec; 19(9):583-7. PubMed ID: 9872340 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin. Medina L; García L; Pérez R; Fernández A; Jung H J Pharm Pharmacol; 1998 Dec; 50(12):1393-6. PubMed ID: 10052855 [TBL] [Abstract][Full Text] [Related]
10. Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits. García AL; Medina RL; Pérez MR; Jung CH Biopharm Drug Dispos; 2003 Jul; 24(5):205-9. PubMed ID: 12784320 [TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacodynamics and brain distribution of E-delta 2-valproate and valproate in rats. Semmes RL; Shen DD Epilepsia; 1991; 32(2):232-41. PubMed ID: 2004628 [TBL] [Abstract][Full Text] [Related]
12. Effects of 3-hydroxy,3-ethyl,3-phenylpropionamide (HEPP) on rat models of generalized and focal epilepsy. Brailowsky S; Montiel T; Hernández E; Marescaux C; Vergnes M Epilepsy Res; 1992 May; 11(3):167-72. PubMed ID: 1396531 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat. Shen DD; Levy RH; Moor MJ; Savitch JL Epilepsy Res; 1990; 7(1):40-8. PubMed ID: 2292245 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats. Koo TS; Kim SJ; Ha DJ; Baek M; Moon H Arch Pharm Res; 2011 Dec; 34(12):2059-64. PubMed ID: 22210031 [TBL] [Abstract][Full Text] [Related]
16. Effect of ACEA--a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Andres-Mach M; Zolkowska D; Barcicka-Klosowska B; Haratym-Maj A; Florek-Luszczki M; Luszczki JJ Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):301-9. PubMed ID: 22789660 [TBL] [Abstract][Full Text] [Related]
17. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480 [TBL] [Abstract][Full Text] [Related]
18. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Löscher W; Hönack D; Fassbender CP; Nolting B Epilepsy Res; 1991 Apr; 8(3):171-89. PubMed ID: 1907909 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic studies of a novel anticonvulsant, 2-(4-chlorophenyl)amino-2-(4-pyridyl)ethane, in rats. Nnane IP; Kadaba PK Pharmacol Res; 2004 Feb; 49(2):177-83. PubMed ID: 14643698 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]